Targeting GRPR in urological cancers—from basic research to clinical application
| Autor: | Rosalba Mansi, Jean Claude Reubi, Helmut R. Mäcke, Achim Fleischmann |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Regulation of gene expression
Urologic Neoplasms Pathology medicine.medical_specialty Biomedical Research business.industry Urology medicine.medical_treatment Urological cancers Gene Expression Regulation Neoplastic Receptors Bombesin Radiation therapy Drug Delivery Systems medicine.anatomical_structure Prostate Basic research Gastrin-releasing peptide medicine Cancer research Animals Humans Cytotoxic T cell Receptor business hormones hormone substitutes and hormone antagonists |
| Zdroj: | Nature Reviews Urology. 10:235-244 |
| ISSN: | 1759-4820 1759-4812 |
| DOI: | 10.1038/nrurol.2013.42 |
| Popis: | Gastrin releasing peptide (GRP) is a regulatory peptide that acts through its receptor (GRPR) to regulate physiological functions in various organs. GRPR is overexpressed in neoplastic cells of most prostate cancers and some renal cell cancers and in the tumoral vessels of urinary tract cancers. Thus, targeting these tumours with specifically designed GRP analogues has potential clinical application. Potent and specific radioactive, cytotoxic or nonradioactive GRP analogues have been designed and tested in various animal tumour models with the aim of receptor targeting for tumour diagnosis or therapy. All three categories of compound were found suitable for tumour targeting in animal models. The cytotoxic and nonradioactive GRP analogues have not yet shown convincing tumour-reducing effects in human trials; however, the first clinical studies of radioactive GRP analogues--both agonists and antagonists--suggest promising opportunities for both diagnostic tumour imaging and radiotherapy of prostate and other GRPR-expressing cancers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|